Indonesian Political, Business & Finance News

Lupus Challenges in Indonesia: High Mortality Rates and New Therapeutic Innovations

| | Source: Media Indonesia Translated from Indonesian | Social Policy
Lupus Challenges in Indonesia: High Mortality Rates and New Therapeutic Innovations
Image: Media Indonesia

Indonesia is facing serious challenges in managing Systemic Lupus Erythematosus (SLE). Data shows approximately 1.4 million SLE patients in the country with an 8.1% mortality rate. This mortality rate places Indonesia among the highest globally. Ironically, despite these high figures, many patients face delayed diagnosis. Medical confirmation often comes only after permanent organ damage has occurred. In response, AstraZeneca Indonesia is leveraging World Lupus Day to bolster its ‘From Burden to Living Well’ educational initiative. SLE is a chronic autoimmune disease where the immune system attacks healthy tissues. It triggers chronic inflammation affecting the skin, joints, kidneys, and central nervous system. Due to its diverse symptoms mimicking other conditions, SLE is often called the ‘disease of a thousand faces’. Dr Sandra Sinthya Langow, SpPD-KR, explained that SLE clinical manifestations can appear gradually or suddenly. ‘Patients experience extreme fatigue, joint pain, and skin rashes. The main clinical challenge is delayed diagnosis due to non-specific symptoms,’ she said. With medical research advances, SLE treatment focus has shifted. Previously centred on managing flares, the current goal is achieving remission—consistently low disease activity. A recent breakthrough in Indonesia is Anifrolumab, the first biological therapy targeting the Type I Interferon pathway—the primary mechanism driving persistent inflammation in SLE patients. ‘A deeper understanding of Type I Interferon’s role enables more targeted therapy. The aim is rapid disease control, remission, and protection against long-term organ damage,’ said Dr Feddy, Medical Director at AstraZeneca Indonesia. AstraZeneca Indonesia’s President Director, Esra Erkomay, stressed public awareness is key. Through cross-sector collaboration, the company has reached over 87,000 young Indonesians via health education programmes. ‘With earlier diagnosis and proper treatment, SLE patients in Indonesia can move from disease burden to better quality of life,’ Esra concluded. Despite being chronic, experts stress SLE patients can maintain a quality life. Key factors include treatment adherence, regular doctor check-ups, and access to new medical innovations that reduce reliance on long-term high-side-effect drugs like glucocorticoids. (Z-1)

More from 27 May 2026 →

Cite this article
Source: jawawa.id (https://jawawa.id/newsitem/lupus-challenges-in-indonesia-high-mortality-rates-and-new-therapeutic-innovations-1779899242)
Originally published by Media Indonesia (https://mediaindonesia.com/humaniora/894224/tantangan-lupus-di-indonesia-angka-mortalitas-tinggi-dan-inovasi-terapi-terbaru), translated from Indonesian
Print